Thrombolysis with tissue plasminogen activator in patients with acute myocardial infarction

Research output: Contribution to journalArticle


Thrombolytic agents are being employed clinically in increasing numbers of patients in the attempt to eliminate occlusive coronary thrombi in patients with evolving myocardial infarction. When administered by the intracoronary route, streptokinase lyses is successful in coronary thrombi in more than two-thirds of patients, but when administered intravenously is successful in only one-third. Since streptokinase is a nonselective plasminogen activator, it induces fibrinogenolysis when administered selectively or systematically with an attendant marked reduction in plasma fibrinogen levels and significant bleeding complications. In contrast, the action of tissue plasminogen activator (t-Pa) is relatively selective for fibrinolysis (as opposed to fibrinogenolysis). It induces coronary thrombolysis in at least 60% of patients when administered either into a coronary ostium or a peripheral vein without producing substantial reductions in circulating fibrinogen. Bleeding complications are modest and usually related to high administered doses and concomitant heparinization, and occur primarily at sites of vascular access. Thus, t-Pa appears to be a promising agent for thrombolytic treatment of patients with evolving acute myocardial infarction.

Original languageEnglish
Pages (from-to)281-289
Number of pages9
JournalJournal of Protein Chemistry
Issue number4
StatePublished - Aug 1 1986


  • infarct size
  • myocardial infarction
  • positron emission tomography
  • thrombolysis
  • tissue plasminogen activator

Fingerprint Dive into the research topics of 'Thrombolysis with tissue plasminogen activator in patients with acute myocardial infarction'. Together they form a unique fingerprint.

  • Cite this